Stocktoria
Lifevantage Corp LFVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-09-12
Lifevantage Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $228.5M | $200.2M | $213.4M | $206.4M | $220.2M |
| Gross profit | $183.7M | $158.7M | $170.0M | $168.3M | $182.0M |
| R&D expense | $1.4M | $700,000 | $600,000 | $700,000 | $700,000 |
| SG&A expense | $69.2M | $68.5M | $71.1M | $63.4M | $60.8M |
| Operating income | $12.2M | $4.3M | $4.3M | $7.6M | $17.6M |
| Interest expense | — | -$430,000 | -$198,000 | $10,000 | $17,000 |
| Income tax | $2.4M | $1.4M | $1.5M | $1.6M | $4.3M |
| Net income | $9.8M | $2.9M | $2.5M | $3.1M | $12.9M |
| EPS (diluted) | $0.75 | $0.23 | $0.20 | $0.24 | $0.90 |
| Operating cash flow | $11.9M | $12.2M | $6.8M | $8.0M | $16.3M |
| Free cash flow | $10.5M | $10.0M | $3.8M | $6.4M | $12.5M |
| Cash & equivalents | $20.2M | $16.9M | $21.6M | $20.2M | $23.2M |
| Inventory | $20.7M | $15.1M | $16.1M | $16.5M | $16.1M |
| Total assets | $72.0M | $60.3M | $66.1M | $70.7M | $78.7M |
| Total liabilities | $37.3M | $34.3M | $31.5M | $39.2M | $41.9M |
| Shareholders' equity | $34.6M | $26.0M | $34.6M | $31.5M | $36.8M |
Source: SEC EDGAR filings · CIK 0000849146 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.